Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 36, 2022 - Issue 5
533
Views
5
CrossRef citations to date
0
Altmetric
SHORT COMMUNICATION

Antileishmanial and cytotoxic activity of secondary metabolites from Taberneamontana ventricosa and two aloe species

ORCID Icon, , , , , , , , ORCID Icon, , & show all
Pages 1365-1369 | Received 31 Aug 2020, Accepted 01 Jan 2021, Published online: 18 Jan 2021
 

Abstract

In this study, the antileishmanial and cytotoxic activities of secondary metabolites isolated from Tabernaemontana ventricosa Hochst. ex A. DC., Aloe tororoana Reynolds, and Aloe schweinfurthii var. labworana Reynolds were investigated. Overall, nineteen known compounds were isolated from the three plant species. The compounds were characterized based on their spectroscopic data. Voacristine and aloenin were the most active compounds against promastigotes of antimony-sensitive Leishmania donovani (IC50 11 ± 5.2 μM and 26 ± 6.5 µM, respectively) with low toxicity against RAW264.7, murine monocyte/macrophage-like cells. The in silico docking evaluation and in vitro NO generation assay also substantially support the antileishmanial effects of these compounds. In a cytotoxicity assay against cancer and normal cell lines, ursolic acid highly inhibited proliferation of lung cancer cells, A549 (IC50 6.61 ± 0.7 μM) while voacristine was moderately active against human liver cancer cells, HepG2 (IC50 23.0 ± 0.0 μM). All other compounds were inactive against the test parasites and cell lines.

Acknowledgements

AM is grateful to the German Academic Exchange Services (DAAD) for a Ph.D. scholarship awarded through the Natural Products Research Network for Eastern and Central Africa (NAPRECA).

Disclosure statement

The authors declare no conflict of interest.

Additional information

Funding

This research was partly supported by small research grants from Busitema University (DGSRI-SRG2020-01).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.